$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000122460822000019 Filed on May 06, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$842.9M	$1.006B
YoY Change	-16.21%	40.27%
Cost Of Revenue	$346.7M	$459.1M
YoY Change	-24.48%	-6.46%
Gross Profit	$496.2M	$546.9M
YoY Change	-9.27%	141.56%
Gross Profit Margin	58.87%	54.36%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$112.7M	$108.7M
YoY Change	3.68%	82.38%
% of Gross Profit	22.71%	19.88%
Operating Expenses	$669.8M	$791.9M
YoY Change	-15.42%	4.92%
Operating Profit	$68.00M	$96.90M
YoY Change	-29.82%	-8.15%
Interest Expense	$23.80M	$24.10M
YoY Change	-1.24%	-27.84%
% of Operating Profit	35.0%	24.87%
Other Income/Expense, Net
YoY Change
Pretax Income	$149.3M	$190.0M
YoY Change	-21.42%	-367.61%
Income Tax	$37.00M	$42.60M
% Of Pretax Income	24.78%	22.42%
Net Earnings	$112.3M	$147.4M
YoY Change	-23.81%	-795.28%
Net Earnings / Revenue	13.32%	14.65%
Basic Earnings Per Share	$0.95	$1.10
Diluted Earnings Per Share	$0.93	$1.08
COMMON SHARES
Basic Shares Outstanding	118.6M shares	134.1M shares
Diluted Shares Outstanding	121.0M shares	136.7M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$594.0M	$738.9M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$27.43B	$26.86B
YoY Change	2.14%	10.71%
Other Assets	$534.2M	$358.0M
YoY Change	49.22%	-49.08%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$35.47B	$34.66B
YoY Change	2.33%	3.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$3.911B	$3.930B
YoY Change	-0.48%	3.8%
Other Long-Term Liabilities	$912.3M	$925.0M
YoY Change	-1.37%	8.7%
Total Long-Term Liabilities	$4.824B	$4.855B
YoY Change	-0.65%	4.7%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities	$4.824B	$4.855B
Total Liabilities	$31.78B	$29.80B
YoY Change	6.64%	2.86%
SHAREHOLDERS EQUITY
Retained Earnings	$1.224B	$883.5M
YoY Change	38.48%	70.59%
Common Stock	$2.087B	$2.459B
YoY Change	-15.14%	-8.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.691B	$4.861B
YoY Change
Total Liabilities & Shareholders Equity	$35.47B	$34.66B
YoY Change	2.33%	5.88%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	$112.3M	$147.4M
YoY Change	-23.81%	-795.28%
Depreciation, Depletion And Amortization	$112.7M	$108.7M
YoY Change	3.68%	82.38%
Cash From Operating Activities	$56.40M	$89.40M
YoY Change	-36.91%	-28.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$13.30M	$53.60M
YoY Change	-75.19%	634.25%
Cash From Investing Activities	-$1.010B	-$334.0M
YoY Change	202.49%	87.43%
FINANCING ACTIVITIES
Cash Dividend Paid	$16.10M	$16.30M
YoY Change	-1.23%	0.62%
Common Stock Issuance & Retirement, Net	$105.8M	$90.30M
YoY Change	17.17%	5.86%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$816.2M	-$8.400M
YoY Change	-9816.67%	-83.75%
NET CHANGE
Cash From Operating Activities	$56.40M	$89.40M
Cash From Investing Activities	-$1.010B	-$334.0M
Cash From Financing Activities	$816.2M	-$8.400M
Net Change In Cash	-$137.7M	-$253.0M
YoY Change	-45.57%	142.8%
FREE CASH FLOW
Cash From Operating Activities	$56.40M	$89.40M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001224608
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-31792
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	CNO Financial Group, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-3108137
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	11825 N. Pennsylvania Street
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
CY2022Q1	dei	City Area Code CityAreaCode	(317)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	817-6100
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	115888908	shares
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	36600000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	22989300000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	21867600000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	23479400000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	24805400000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	91000000.0	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	131100000	USD
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5100000	USD
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5600000	USD
CY2022Q1	us-gaap	Notes Receivable Net NotesReceivableNet	1213300000	USD
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	1218600000	USD
CY2022Q1	us-gaap	Policy Loans Receivable PolicyLoansReceivable	119500000	USD
CY2021Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	120200000	USD
CY2022Q1	us-gaap	Trading Securities Debt TradingSecuritiesDebt	223000000.0	USD
CY2021Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	227200000	USD
CY2022Q1	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	5900000	USD
CY2021Q4	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	3700000	USD
CY2022Q1	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1198900000	USD
CY2021Q4	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1206800000	USD
CY2022Q1	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1180800000	USD
CY2021Q4	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1199600000	USD
CY2022Q1	us-gaap	Other Investments OtherInvestments	1121800000	USD
CY2021Q4	us-gaap	Other Investments OtherInvestments	1224000000	USD
CY2022Q1	us-gaap	Investments Investments	27428800000	USD
CY2021Q4	us-gaap	Investments Investments	28926100000	USD
CY2022Q1	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	546000000.0	USD
CY2021Q4	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	632100000	USD
CY2022Q1	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	48000000.0	USD
CY2021Q4	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	99600000	USD
CY2022Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	227900000	USD
CY2021Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	216400000	USD
CY2022Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	222800000	USD
CY2021Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	222600000	USD
CY2022Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1487600000	USD
CY2021Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1112000000	USD
CY2022Q1	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	3000000.0	USD
CY2021Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	3000000.0	USD
CY2022Q1	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4298200000	USD
CY2021Q4	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4354300000	USD
CY2022Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	534200000	USD
CY2021Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	118300000	USD
CY2022Q1	us-gaap	Separate Account Assets SeparateAccountAssets	3600000	USD
CY2021Q4	us-gaap	Separate Account Assets SeparateAccountAssets	3900000	USD
CY2022Q1	us-gaap	Other Assets OtherAssets	671000000.0	USD
CY2021Q4	us-gaap	Other Assets OtherAssets	519100000	USD
CY2022Q1	us-gaap	Assets Assets	35468100000	USD
CY2021Q4	us-gaap	Assets Assets	36204400000	USD
CY2022Q1	us-gaap	Policyholder Funds PolicyholderFunds	14546300000	USD
CY2021Q4	us-gaap	Policyholder Funds PolicyholderFunds	13689700000	USD
CY2022Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11646500000	USD
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11670700000	USD
CY2022Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	507300000	USD
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	501800000	USD
CY2022Q1	us-gaap	Unearned Premiums UnearnedPremiums	250000000.0	USD
CY2021Q4	us-gaap	Unearned Premiums UnearnedPremiums	246700000	USD
CY2022Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3600000	USD
CY2021Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3900000	USD
CY2022Q1	us-gaap	Other Liabilities OtherLiabilities	912300000	USD
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	830900000	USD
CY2022Q1	cno	Investment Borrowings InvestmentBorrowings	1640500000	USD
CY2021Q4	cno	Investment Borrowings InvestmentBorrowings	1715800000	USD
CY2022Q1	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1133100000	USD
CY2021Q4	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1147900000	USD
CY2022Q1	us-gaap	Notes Payable NotesPayable	1137600000	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	1137300000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	31777200000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	30944700000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117241006	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117241006	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120377152	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120377152	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1200000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1200000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2085700000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2184200000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	380500000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1947100000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1223500000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1127200000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	3690900000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5259700000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35468100000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36204400000	USD
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	625000000.0	USD
CY2021Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	632400000	USD
CY2022Q1	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	277500000	USD
CY2021Q1	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	282700000	USD
CY2022Q1	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	-69300000	USD
CY2021Q1	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	55500000	USD
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	18800000	USD
CY2021Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-6000000.0	USD
CY2022Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-51500000	USD
CY2021Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	3200000	USD
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32700000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2800000	USD
CY2022Q1	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	42400000	USD
CY2021Q1	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	38200000	USD
CY2022Q1	us-gaap	Revenues Revenues	842900000	USD
CY2021Q1	us-gaap	Revenues Revenues	1006000000	USD
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	346700000	USD
CY2021Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	459100000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	23800000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	24100000	USD
CY2022Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	103900000	USD
CY2021Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	99700000	USD
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	219200000	USD
CY2021Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	233100000	USD
CY2022Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	693600000	USD
CY2021Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	816000000.0	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	149300000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	190000000.0	USD
CY2022Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	37000000.0	USD
CY2021Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	42600000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	147400000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118622000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134140000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2021Q1	cno	Other Comprehensive Income Loss Reclassification Adjustment For Amortization Of Present Value Of Future Profits And Deferred Acquisition Costs Related To Net Realized Investment Gains Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForAmortizationOfPresentValueOfFutureProfitsAndDeferredAcquisitionCostsRelatedToNetRealizedInvestmentGainsBeforeTax	0	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.10
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121002000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	136653000	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.93
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.08
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	147400000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-2435100000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-1198200000	USD
CY2022Q1	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisition Costs Unrealized Holding Gain Loss Arising During Periodbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionCostsUnrealizedHoldingGainLossArisingDuringPeriodbeforeTax	-257500000	USD
CY2021Q1	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisition Costs Unrealized Holding Gain Loss Arising During Periodbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionCostsUnrealizedHoldingGainLossArisingDuringPeriodbeforeTax	-83600000	USD
CY2022Q1	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisitions Costs Reductionin Premium Deficienciesbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionsCostsReductioninPremiumDeficienciesbeforeTax	165000000.0	USD
CY2021Q1	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisitions Costs Reductionin Premium Deficienciesbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionsCostsReductioninPremiumDeficienciesbeforeTax	262500000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-7800000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	500000	USD
CY2022Q1	cno	Other Comprehensive Income Loss Reclassification Adjustment For Amortization Of Present Value Of Future Profits And Deferred Acquisition Costs Related To Net Realized Investment Gains Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForAmortizationOfPresentValueOfFutureProfitsAndDeferredAcquisitionCostsRelatedToNetRealizedInvestmentGainsBeforeTax	-100000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-2004900000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-852600000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-438300000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-184600000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1566600000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-668000000.0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1454300000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-520600000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5484200000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	147400000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	184600000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-668000000.0	USD
CY2021Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	100000000.0	USD
CY2021Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16200000	USD
CY2021Q1	cno	Stock Based Compensation StockBasedCompensation	13300000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	4860700000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5259700000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	438300000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1566600000	USD
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	100000000.0	USD
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16000000.0	USD
CY2022Q1	cno	Stock Based Compensation StockBasedCompensation	1500000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	3690900000	USD
CY2022Q1	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	580800000	USD
CY2021Q1	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	598900000	USD
CY2022Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	260500000	USD
CY2021Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	251100000	USD
CY2022Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	49800000	USD
CY2021Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	38200000	USD
CY2022Q1	cno	Insurance Policy Benefits InsurancePolicyBenefits	416800000	USD
CY2021Q1	cno	Insurance Policy Benefits InsurancePolicyBenefits	427200000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	9700000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	10500000	USD
CY2022Q1	cno	Policy Acquisition Costs PolicyAcquisitionCosts	82800000	USD
CY2021Q1	cno	Policy Acquisition Costs PolicyAcquisitionCosts	70700000	USD
CY2022Q1	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	310800000	USD
CY2021Q1	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	273700000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14600000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	56400000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	89400000	USD
CY2022Q1	cno	Sales Of Investments SalesOfInvestments	1520600000	USD
CY2021Q1	cno	Sales Of Investments SalesOfInvestments	509200000	USD
CY2022Q1	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	494900000	USD
CY2021Q1	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	754900000	USD
CY2022Q1	cno	Purchases Of Investments PurchasesOfInvestments	2995200000	USD
CY2021Q1	cno	Purchases Of Investments PurchasesOfInvestments	1530300000	USD
CY2022Q1	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-17300000	USD
CY2021Q1	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-14200000	USD
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	13300000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	53600000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1010300000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-334000000.0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4000000.0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12400000	USD
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	109800000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	102700000	USD
CY2022Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	16100000	USD
CY2021Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	16300000	USD
CY2022Q1	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1392600000	USD
CY2021Q1	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	444900000	USD
CY2022Q1	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	364200000	USD
CY2021Q1	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	345700000	USD
CY2022Q1	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	0	USD
CY2021Q1	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	200000000.0	USD
CY2022Q1	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	75300000	USD
CY2021Q1	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	200500000	USD
CY2022Q1	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	15000000.0	USD
CY2021Q1	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	500000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	816200000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8400000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-137700000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-253000000.0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	731700000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	991900000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	594000000.0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738900000	USD
CY2022Q1	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	900800000	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	2963300000	USD
CY2022Q1	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-387900000	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-23100000	USD
CY2022Q1	cno	Accumulated Other Comprehensive Income Loss Adjustment To Present Value Of Future Profits AccumulatedOtherComprehensiveIncomeLossAdjustmentToPresentValueOfFutureProfits	-400000	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Loss Adjustment To Present Value Of Future Profits AccumulatedOtherComprehensiveIncomeLossAdjustmentToPresentValueOfFutureProfits	-8300000	USD
CY2022Q1	cno	Accumulated Other Comprehensive Income Loss Adjustment To Deferred Policy Acquisition Costs AccumulatedOtherComprehensiveIncomeLossAdjustmentToDeferredPolicyAcquisitionCosts	-31200000	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Loss Adjustment To Deferred Policy Acquisition Costs AccumulatedOtherComprehensiveIncomeLossAdjustmentToDeferredPolicyAcquisitionCosts	-420200000	USD
CY2022Q1	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	0	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-25500000	USD
CY2022Q1	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	-100800000	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	-539100000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	380500000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1947100000	USD
CY2021Q4	cno	Reduction To Present Value Of Future Profits Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized ReductionToPresentValueOfFutureProfitsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-7300000	USD
CY2021Q4	cno	Reduction To Deferred Acquisition Costs Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized ReductionToDeferredAcquisitionCostsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-132200000	USD
CY2021Q4	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-25500000	USD
CY2021Q4	cno	Increase To Deferred Tax Assets Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized IncreaseToDeferredTaxAssetsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	35800000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	60600000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	59000000.0	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	1561700000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1557900000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	2292600000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	2266700000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12909900000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	13456300000	USD
CY2022Q1	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16824800000	USD
CY2022Q1	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	17339900000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	6164500000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6139500000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	22989300000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	23479400000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	80300000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	80500000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	1147400000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1205600000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1458400000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1573700000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	13409900000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	15913300000	USD
CY2021Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16096000000	USD
CY2021Q4	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	18773100000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	5771600000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6032300000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	21867600000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	24805400000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	5155300000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	251200000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	149500000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	8900000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	5304800000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	260100000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1698600000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	15100000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	122200000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3400000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	1820800000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	18500000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	14400000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	15000000.0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	400000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	36600000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	2200000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	1800000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	1500000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	200000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	5300000	USD
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5600000	USD
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11800000	USD
CY2022Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	500000	USD
CY2021Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	3000000.0	USD
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2021Q1	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
CY2021Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2021Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5100000	USD
CY2021Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8800000	USD
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	18800000	USD
CY2021Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-6000000.0	USD
CY2022Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	30700000	USD
CY2021Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-9600000	USD
CY2022Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1200000	USD
CY2021Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1800000	USD
CY2022Q1	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-19600000	USD
CY2021Q1	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-4600000	USD
CY2022Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-51500000	USD
CY2021Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	3200000	USD
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32700000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2800000	USD
CY2022Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2200000	USD
CY2021Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	9700000	USD
CY2022Q1	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-5200000	USD
CY2021Q1	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-1300000	USD
CY2022Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-12800000	USD
CY2021Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-1600000	USD
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32700000	USD
CY2022Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	30700000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2800000	USD
CY2021Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-9600000	USD
CY2022Q1	cno	Numberof Investmentsin Defaultor Considered Nonperforming NumberofInvestmentsinDefaultorConsideredNonperforming	0	investment
CY2022Q1	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	786600000	USD
CY2021Q1	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	215500000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	112300000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	112300000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	147400000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	147400000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118622000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134140000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2380000	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2513000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121002000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	136653000	shares
CY2022Q1	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2022Q1	cno	Segment Revenues SegmentRevenues	869100000	USD
CY2021Q1	cno	Segment Revenues SegmentRevenues	1001900000	USD
CY2022Q1	cno	Segment Expenses SegmentExpenses	801100000	USD
CY2021Q1	cno	Segment Expenses SegmentExpenses	905000000.0	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	68000000.0	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	96900000	USD
CY2022Q1	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	16900000	USD
CY2021Q1	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	21700000	USD
CY2022Q1	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	51100000	USD
CY2021Q1	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	75200000	USD
CY2022Q1	us-gaap	Revenues Revenues	842900000	USD
CY2021Q1	us-gaap	Revenues Revenues	1006000000	USD
CY2022Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	693600000	USD
CY2021Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	816000000.0	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	149300000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	190000000.0	USD
CY2022Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	37000000.0	USD
CY2021Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	42600000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	147400000	USD
CY2022Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	99000000	USD
CY2022Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-79400000	USD
CY2021Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	40600000	USD
CY2022Q1	us-gaap	Ceded Premiums Written CededPremiumsWritten	52000000	USD
CY2021Q1	us-gaap	Ceded Premiums Written CededPremiumsWritten	54800000	USD
CY2022Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	93900000	USD
CY2021Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	92300000	USD
CY2022Q1	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4900000	USD
CY2021Q1	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	5300000	USD
CY2022Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	6100000	USD
CY2021Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	8600000	USD
CY2022Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4400000	USD
CY2021Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	14000000.0	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	32600000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	28600000	USD
CY2022Q1	cno	Income Tax Expense Benefit Total IncomeTaxExpenseBenefitTotal	37000000.0	USD
CY2021Q1	cno	Income Tax Expense Benefit Total IncomeTaxExpenseBenefitTotal	42600000	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2021Q1	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2021Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.248
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.224
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	237000000.0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	241400000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2300000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	348000000.0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	390700000	USD
CY2022Q1	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	171300000	USD
CY2021Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	158300000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27500000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	774500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	820200000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	39800000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	48200000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	111200000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	119400000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	105400000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	540400000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	256400000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	708000000.0	USD
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	518100000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	112200000	USD
CY2022Q1	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	16100000	USD
CY2021Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	6100000	USD
CY2022Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	534200000	USD
CY2021Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	118300000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	518100000	USD
CY2022Q1	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2022Q1	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2022Q1	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0163
CY2022Q1	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2022Q1	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	1128400000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2300000	USD
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.13
CY2022Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	12400000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	12700000	USD
CY2022Q1	us-gaap	Notes Payable NotesPayable	1137600000	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	1137300000	USD
CY2022Q1	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	100000000	USD
CY2022Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	266900000	USD
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16000000	USD
CY2022Q1	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	4700000	USD
CY2021Q1	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	3900000	USD
CY2022Q1	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	7500000	USD
CY2021Q1	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	6200000	USD
CY2022Q1	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	58400000	USD
CY2021Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	61200000	USD
CY2022Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION AND OTHER LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2019, Bankers Conseco Life Insurance Company ("BCLIC") and Washington National commenced an action entitled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Wilmington Trust, National Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "Wilmington Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the Wilmington Action, BCLIC and Washington National assert claims against Wilmington Trust, National Association ("Wilmington") for breaching its express contractual obligations under four trust agreements pursuant to which Wilmington was the trustee in regard to trust assets ceded as part of reinsurance agreements with Beechwood Re Ltd. ("BRe"), as well as for breaching its fiduciary duties to BCLIC and Washington National. The Court granted Wilmington's motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On April 20, 2021, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated breach of contract and breach of fiduciary duty claims against Wilmington. The Wilmington Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2019, the Joint Official Liquidators of Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) and Principal Growth Strategies, LLC, commenced suit against, among others, CNO Financial Group, Inc., BCLIC, Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties are vigorously contesting the plaintiff's claims. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. After the stay is lifted, the court will address the CNO Parties’ and other defendants’ motions to dismiss the Amended Complaint on numerous other grounds.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2019, BCLIC and Washington National commenced an action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bankers Conseco Life Insurance Company and Washington National Insurance Company v. KPMG LLP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Supreme Court of the State of New York, County of New York, Commercial Division (the "KPMG Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the KPMG Action, BCLIC and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington National assert claims against KPMG LLP ("KPMG") for aiding and abetting fraud, constructive fraud and negligent misrepresentation arising from KPMG's alleged role in the Platinum Partners' scheme to defraud BCLIC and Washington National into reinsuring its long-term care business with BRe. The Court granted KPMG’s motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On December 1, 2020, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated the aiding and abetting claim against KPMG. The KPMG Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries. Such examination has included inquiries related to the use of data available on the U.S. Social Security Administration's Death Master File ("SSADMF") to identify instances where benefits under life insurance policies, annuities and retained asset accounts are payable. We are continuing to provide information to the examiners in response to their requests. A total of 42 states and the District of Columbia participated in this examination. In November 2018, we entered into an agreement for compliance with laws and regulations concerning the identification, reporting and escheatment of unclaimed contract benefits or abandoned funds (the "Global Resolution Agreement"). Under the terms of the Global Resolution Agreement, a third-party auditor acting on behalf of the signatory jurisdictions is comparing expanded matching criteria to the SSADMF to identify deceased insureds and contract holders where a valid claim has not been made.</span></div>
CY2022Q1	cno	Number Of States Participating In Examination Of Compliance With Unclaimed Property Laws NumberOfStatesParticipatingInExaminationOfComplianceWithUnclaimedPropertyLaws	42	state
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	112300000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	147400000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112700000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	108700000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	22500000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	25900000	USD
CY2022Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-113700000	USD
CY2021Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-3900000	USD
CY2022Q1	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	52200000	USD
CY2021Q1	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-87100000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	82800000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	70700000	USD
CY2022Q1	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-32700000	USD
CY2021Q1	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-2800000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-79500000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-33700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	56400000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	89400000	USD
CY2022Q1	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	7200000	USD
CY2021Q1	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	5600000	USD
CY2022Q1	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	1198900000	USD
CY2022Q1	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	900000	USD
CY2022Q1	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	13100000	USD
CY2022Q1	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	5900000	USD
CY2022Q1	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	1180800000	USD
CY2022Q1	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-3200000	USD
CY2022Q1	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	800000	USD
CY2022Q1	cno	Variable Interest Entities Ney Gain Loss From Change In Market Value Of Other Investments VariableInterestEntitiesNeyGainLossFromChangeInMarketValueOfOtherInvestments	200000	USD
CY2022Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2200000	USD
CY2022Q1	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	800000	USD
CY2022Q1	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	11700000	USD
CY2021Q1	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	4100000	USD
CY2021Q1	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	5600000	USD
CY2021Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	9700000	USD
CY2021Q1	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	5600000	USD
CY2021Q1	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	27200000	USD
CY2022Q1	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2022Q1	cno	Investments Held In Limited Partnerships InvestmentsHeldInLimitedPartnerships	620700000	USD
CY2022Q1	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	244900000	USD
CY2022Q1	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.89
CY2022Q1	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.79
CY2022Q1	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.62

Files In Submission

Name	View Source	Status
0001224608-22-000019-index-headers.html	Edgar Link	pending
0001224608-22-000019-index.html	Edgar Link	pending
0001224608-22-000019.txt	Edgar Link	pending
0001224608-22-000019-xbrl.zip	Edgar Link	pending
cno-20220331.htm	Edgar Link	pending
cno-20220331.xsd	Edgar Link	pending
cno-20220331_cal.xml	Edgar Link	unprocessable
cno-20220331_def.xml	Edgar Link	unprocessable
cno-20220331_htm.xml	Edgar Link	completed
cno-20220331_lab.xml	Edgar Link	unprocessable
cno-20220331_pre.xml	Edgar Link	unprocessable
cno03312022ex101.htm	Edgar Link	pending
cno03312022ex102.htm	Edgar Link	pending
cno03312022ex311.htm	Edgar Link	pending
cno03312022ex312.htm	Edgar Link	pending
cno03312022ex321.htm	Edgar Link	pending
cno03312022ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2022 Q1 Form 10-Q Financial Statement

#000122460822000019 Filed on May 06, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2022 Q1 Form 10-Q Financial Statement

#000122460822000019 Filed on May 06, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno